Home / Leaderboard / EcoR1 Capital, LLC
EcoR1 Capital, LLC
Oleg Nodelman · Hedge Fund · Long/Short Equity
EcoR1 Capital, LLC is a San Francisco-based biotechnology investment firm founded in 2013 by Oleg Nodelman. The firm specializes in the life sciences sector, providing capital and strategic partnership to innovative companies throughout their research and development lifecycle. With a focus on identifying scientific breakthroughs that can improve patient outcomes, EcoR1 manages a diverse portfolio spanning from early-stage private ventures to established public entities. The firm utilizes a fundamental, research-driven approach, leveraging its team's deep scientific and financial expertise to identify undervalued opportunities and navigate the complexities of clinical and regulatory landscapes. EcoR1 is dedicated to fueling the advancement of medical therapies and supporting the long-term success of the global biotech ecosystem.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +66.6% |
| YTD return | +27.3% |
| Sharpe ratio | 4.04 |
| Win rate | 61% |
| AUM | $2.2B |
| Inception | Oct 1, 2025 |
| Updated | Sep 21, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $2.2B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://ecor1cap.com/ |
Current Holdings
Updated on Sep 21, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| ZYME | Zymeworks Inc. Common Stock | 30.3% | +24.3% |
| ANAB | AnaptysBio Inc | 20.6% | +15.7% |
| AKTS | Aktis Oncology, Inc. Common stock | 7.1% | -5.8% |
| TRAX | First Tracks Biotherapeutics | 6.4% | +28.4% |
| ETON | Eton Pharmaceuticals Inc | 6.0% | +72.7% |
| CGON | CG Oncology, Inc. Common stock | 5.2% | +14.8% |
| ORIC | Oric Pharmaceuticals Inc | 4.2% | +7.5% |
| CRSP | Crispr Therapeutics AG | 3.8% | -0.7% |
| ANRO | Alto Neuroscience, Inc. | 3.7% | +7.0% |
| LKFT | LKFT | 2.2% | +6.7% |
| NGNE | Neurogene Inc | 2.2% | +26.6% |
| ZBIO | Zenas BioPharma, Inc. Common Stock | 1.2% | +17.9% |
| MBX | MBX Biosciences, Inc. Common Stock | 1.2% | +149.5% |
| FULC | Fulcrum Therapeutics Inc | 1.2% | -1.0% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | 1.1% | -55.8% |
| STOK | Stoke Therapeutics Inc | 1.1% | -11.6% |
| LEGN | Legend Biotech Corp | 0.7% | -7.2% |
| ATRA | Atara Biotherapeutics Inc | 0.7% | +3.1% |
| ODTX | Odyssey Therapeutics, Inc. Common Stock | 0.6% | -7.4% |
| RLAY | Relay Therapeutics Inc | 0.6% | +28.8% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 31, 2026 | BUY | NGNE | 1.6% → 2.2% |
| Aug 31, 2026 | BUY | STOK | 0.0% → 1.1% |
| Aug 31, 2026 | BUY | BBOT | 0.9% → 1.1% |
| Aug 31, 2026 | BUY | ANRO | 2.3% → 3.7% |
| Aug 31, 2026 | SELL | MBX | 1.8% → 1.2% |
Investment Style Analysis
EcoR1 Capital, LLC is widely recognized for employing a Long/Short Equity strategy. As of Sep 21, 2026, the firm oversees approximately $2.2B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Drug Manufacturers - Specialty & Generic sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 31, EcoR1 Capital, LLC made a significant move by increasing exposure to NGNE. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
The firm’s investment philosophy centers on a rigorous, science-first approach to identifying transformative medical innovations. EcoR1 emphasizes 'bilingual synergy,' bridging the gap between scientific discovery and strategic business execution to identify high-conviction opportunities. The firm conducts holistic, multi-dimensional due diligence to evaluate management teams, technical validity, and financing strategies, often targeting overlooked or misunderstood assets in the biotech space. By maintaining a long-term perspective and operating as 'lenders of conviction,' EcoR1 seeks to capture value as clinical milestones are achieved, focusing on companies with the potential to address significant unmet medical needs and deliver superior risk-adjusted returns.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with EcoR1 Capital, LLC.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +4.5%
- Glenview Capital Management, LLC — Larry Robbins · 3M +10.8%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +4.2%
- Redmile Group, LLC — Jeremy Green · 3M +3.2%
Frequently asked questions
How is the simulated portfolio for EcoR1 Capital, LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is EcoR1 Capital, LLC's largest holding?
As of the latest filing, EcoR1 Capital, LLC's top position is Zymeworks Inc. Common Stock (ZYME), representing 30.3% of the portfolio. This reflects a high-conviction bet by the institution.
What is EcoR1 Capital, LLC's historical performance and risk profile?
Our simulation indicates a total return of +66.6% with a win rate of 61%. Notably, the portfolio maintains a Sharpe Ratio of 4.04, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does EcoR1 Capital, LLC primarily invest in?
EcoR1 Capital, LLC has a strong preference for the Biotechnology sector, which makes up 91.8% of their disclosed assets. The portfolio also has exposure to Drug Manufacturers - Specialty & Generic, indicating a specific thematic focus.
Is EcoR1 Capital, LLC's portfolio concentrated or diversified?
EcoR1 Capital, LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 58.0% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has EcoR1 Capital, LLC performed in 2026?
Our AI-simulated model portfolio for EcoR1 Capital, LLC tracks a Year-to-Date (YTD) return of +27.3%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Oleg Nodelman manage EcoR1 Capital, LLC directly?
Yes, Oleg Nodelman serves as the key portfolio manager for EcoR1 Capital, LLC, overseeing the investment strategy and final capital allocation decisions.